Monday, 24 Feb 2020

You are here

Opioids No Better than NSAIDs at Chronic Pain

JAMA reports that the SPACE trial demonstrates patients with chronic back or arthritis pain respond equally to 12 months of either opioids or non-opioid (acetaminophen or NSAIDs) analgesics. (citation source:bit.ly/2tpquTM)

The study enrolled 240 patients from the Veterans Affairs primary care colinics with chronic pain in the back, knees or hips.  Patients were randomized to receive opioid vs nonopioid therapy and over 12 months were assessed for pain-related function (Brief Pain Inventory [BPI] . 

All patients followed a treat-to-target strategy aiming for improved pain and function. Opioid patients were given immediate-release morphine, that could be followed by hydrocodone/acetaminophen, or immediate release oxycodone and lastly a long-acting morphine or oxycodone or fentanyl patches.  

The nonopioid group received acetaminophen or a nonsteroidal anti-inflammatory drug. If ineffective therapy could be escalated to gabapentin, topical lidocaine, pregabalin or even tramadol.

The mean age was 58.3 years, 13% were women, and 97.5% completed the trial.

Groups did not significantly differ on pain-related function over 12 months (overall P = .58).  Pain intensity started at 5.4 for both groups but fell significantly more with nonopioids (3.5) than opioids (4.0) after 12 months (overall P = .03).

On the other hand, adverse events were significantly more common in the opioid group (1.8 vs. 0.9;  P = .03).

These results do not support the use of opioids as initial therapy in those with moderate to severe chronic back pain or hip or knee osteoarthritis pain. These results do not apply to management of cancer related pain.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Half of Opioids Rx Come from 1% of MDs

The BMJ reports that while most US providers are cautious in their prescribing, half of opioid prescriptions are written by 1% of providers.

Between 2003 and 2017, there was an annual average of 669495 providers prescribing 8.9 million opioid prescriptions.

In 2017, 1% of providers accounted for 49% of all opioid doses and 27% of all opioid prescriptions; that's nearly 1000 times more than the middle 1% of prescribers.

Domestic Abuse Linked to Fibromyalgia and Chronic Fatigue

Domestic violence was found to predispose to a higher risk of fibromyalgia and those developing chronic fatigue syndrome.

Researchers studied the association between intimate partner violence (IPV) with fibromyalgia and CFS, using a retrospective open cohort design of patients entered into the “The Heath Improvement Network” database between 1995 and 2017.

A Potential Biomarker for Chronic Fatigue Syndrome Patients

Myalgic encephalomyelitis/chronic fatigue syndrome affects at least 2 million people in the United States and bears tremendous overlap with fibromyalgia - both being difficult to diagnosis because the symptom complex is often unrecognized and these conditions have no biomarker test. 

NIH Conference Review of Chronic Fatigue Syndrome

The current issue of JAMA reviews recent advances on chronic fatigue syndrome, also known as myalgic encephalomyelitis/(ME/CFS), based on a 2-day conference held at the NIH in an April 2019. The NIH 2-day conference reviewed recent progress and new research in several areas described below.

Study Looks at Opioid Use After Knee Surgery

A small study looked at whether reducing the number of opioid tablets prescribed after knee surgery would reduce postoperative use and if preoperative opioid-use education would reduce it even more.